Evidence map›Paper›PMID 34019167›Full record

ArticleRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer2021

Liver Living Donation for Cancer Patients: Benefits, Risks, Justification.

Silvio Nadalin, Lara Genedy, Alfred Königsrainer

Abstract read
PubMed Publisher
In one paragraph

Article in Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Silvio NadalinDirector Department of Surgery and Transplantation, University Hospital, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.
Lara GenedyDirector Department of Surgery and Transplantation, University Hospital, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.
Alfred KönigsrainerDirector Department of Surgery and Transplantation, University Hospital, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany. alfred.koenigsrainer@med.uni-tuebingen.de.
University Children's Hospital Tübingen · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LDLT covers all standard indications for liver transplantation, and the results are similar or even better than for standard DDLT. Due to the donor shortage and long waiting time, LDLT has become a relevant option for patients with liver tumors, provided the expected five-year survival rate is comparable to that of patients receiving a DDLT. Nowadays, LDLT offers the possibility to extend the standard morphometric selection by considering the biological parameters. In the setting of LDLT, we are not only faced with surgical morbidity in the donor, but long-term non-medical problems like psychological complications and financial burden also have to be considered. On the other hand, the benefits to the donor are mainly social and psychological. In LDLT, the donor's altruism is the fundamental ethical principle and it is based on the principles of (1) beneficence (doing good), (2) non-maleficence (avoiding harm), (3) respect for autonomy, and (4) respect for justice (promoting fairness). On top of that, the concept of double equipoise of living organ donation evaluates the relationship between the recipient's need, the donor's risk, and the recipient's outcome. It considers each donor-recipient pair as a unit, analyzing whether the specific recipient's benefit justifies the specific donor's risk in particular oncologic indications. In this light, it is essential to seek adequate informed consent focused on risk, benefits and outcome benefits of both donor and recipient supported by an independent living donor advocate. Finally, the transplant team must protect donors from donation if harm does not justify the expected benefit to the recipient.

Indexed as

Liver TransplantationNeoplasmsHumansInformed ConsentLiverLiving DonorsBenefitsEthical aspectsLiver tumorsLiving donor liver transplantationLong-term resultsrisks and justification

Identifiers

PMID34019167
OpenAlexW3160116562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.